trending Market Intelligence /marketintelligence/en/news-insights/trending/a8o-ervm7i2mxn7qt6lvfg2 content esgSubNav
In This List

Helix, ProMab to develop cell-based treatment for multiple myeloma

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Helix, ProMab to develop cell-based treatment for multiple myeloma

Helix BioPharma Corp. has completed an agreement with ProMab Biotechnologies, Inc. to develop a cell-based therapy to prevent and treat solid tumors.

The Richmond, Ontario-based company will collaborate with ProMab to develop chimeric antigen receptor T cell, or CAR-T, technologies for certain hematological malignancies.

The identified treatment will be developed for multiple myeloma, a type of blood cancer. Helix retains the commercial rights to the CAR-T cell therapy in Canada and Europe.

SNL Image

The program intends to start human trials by early 2019.

Helix said it continues to prioritize its DOS47 drug development, particularly its clinical L-DOS47 and V-DOS47 preclinical programs, both for treating cancers.